Evidence map›Paper›PMID 40352927›Full record

ArticleFrontiers in immunology2025

Chitinase 3-like protein 1: a diagnostic biomarker for early liver fibrosis in autoimmune liver diseases.

Shafei Liu, Conggao Peng, Shijia Xia, Chaonan Li, Xiahong Dai, Xingyu Liu, Meng Zhang, Xiaoping Li, Lingling Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shafei Liu *School of Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Conggao Peng *Department of Infectious Diseases, Key Laboratory of Artificial Organs and Computational Medicine of Zhejiang Province, Shulan(Hangzhou)Hospital, Hangzhou, China.
Shijia XiaSchool of Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Chaonan LiSchool of Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Xiahong DaiDepartment of Infectious Diseases, Key Laboratory of Artificial Organs and Computational Medicine of Zhejiang Province, Shulan(Hangzhou)Hospital, Hangzhou, China.
Xingyu LiuCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Meng ZhangSchool of Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
Xiaoping LiKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Lingling TangDepartment of Infectious Diseases, Key Laboratory of Artificial Organs and Computational Medicine of Zhejiang Province, Shulan(Hangzhou)Hospital, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Chitinase 3-like protein 1 (CHI3L1) is a marker of liver fibrosis produced mainly by hepatic macrophages. However, few studies have assessed the relationship between CHI3L1 and liver fibrosis in autoimmune liver diseases (AILDs). We aimed to explore the diagnostic value of CHI3L1 for liver fibrosis in AILDs and to compare its application differences between AILDs and chronic hepatitis B (CHB) patients. Methods: The fibrotic group was defined as liver stiffness measurement (LSM) > 9.70kPa. Serum CHI3L1 levels were measured by ELISA in 78 AILDs patients, 65 chronic hepatitis B patients. The diagnostic accuracy was evaluated by the area under the receiver operating characteristic curve (AUROC). Results: Serum CHI3L1 levels in AILDs patients were positively correlated with LSM (r=0.750, Conclusion: Serum CHI3L1 is an effective non-invasive indicator for assessing liver fibrosis in AILDs patients and may vary in different etiologies.

Indexed as

Autoimmune DiseasesChitinase-3-Like Protein 1Liver CirrhosisAdultBiomarkersFemaleHepatitis B, ChronicHumansMaleMiddle AgedROC CurveBiomarkersCHI3L1 protein, humanChitinase-3-Like Protein 1autoimmune liver diseaseschitinase 3 like protein 1chronic HBVfibroscanliver fibrosis

Identifiers

PMID40352927
PMCPMC12061858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.